Brokerages predict that Dynavax Technologies Co. (NASDAQ:DVAX) will post earnings per share (EPS) of ($0.34) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Dynavax Technologies’ earnings. The lowest EPS estimate is ($0.37) and the highest is ($0.33). Dynavax Technologies reported earnings per share of ($0.64) during the same quarter last year, which would suggest a positive year over year growth rate of 46.9%. The company is expected to report its next quarterly earnings report on Tuesday, February 25th.
According to Zacks, analysts expect that Dynavax Technologies will report full-year earnings of ($2.04) per share for the current financial year, with EPS estimates ranging from ($2.08) to ($2.00). For the next year, analysts anticipate that the firm will report earnings of ($1.03) per share, with EPS estimates ranging from ($1.11) to ($0.90). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Dynavax Technologies.
Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.10). The firm had revenue of $10.58 million during the quarter, compared to analysts’ expectations of $10.31 million. Dynavax Technologies had a negative return on equity of 399.60% and a negative net margin of 519.95%. The business’s revenue was up 624.7% on a year-over-year basis. During the same quarter last year, the business earned ($0.65) EPS.
A number of brokerages recently issued reports on DVAX. Zacks Investment Research upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Thursday. HC Wainwright restated a “buy” rating on shares of Dynavax Technologies in a research note on Thursday, November 7th. William Blair restated a “buy” rating on shares of Dynavax Technologies in a research note on Friday, August 16th. Finally, BidaskClub upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $12.63.
DVAX stock traded down $0.22 during midday trading on Monday, reaching $5.43. The stock had a trading volume of 1,504,786 shares, compared to its average volume of 1,309,014. The stock has a market cap of $479.68 million, a PE ratio of -2.13 and a beta of 0.56. The company has a debt-to-equity ratio of 5.48, a quick ratio of 4.09 and a current ratio of 4.94. The firm has a fifty day simple moving average of $5.20 and a two-hundred day simple moving average of $4.39. Dynavax Technologies has a 52-week low of $2.60 and a 52-week high of $12.42.
Institutional investors and hedge funds have recently made changes to their positions in the business. Ladenburg Thalmann Financial Services Inc. grew its position in Dynavax Technologies by 95.0% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,984 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 3,402 shares during the period. Bank of Montreal Can grew its position in Dynavax Technologies by 148.4% during the 2nd quarter. Bank of Montreal Can now owns 7,440 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 4,445 shares during the period. Wedbush Securities Inc. acquired a new stake in Dynavax Technologies during the 2nd quarter worth about $42,000. Ingalls & Snyder LLC acquired a new stake in Dynavax Technologies during the 3rd quarter worth about $52,000. Finally, M&T Bank Corp grew its position in Dynavax Technologies by 29.5% during the 2nd quarter. M&T Bank Corp now owns 13,685 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 3,116 shares during the period. 82.36% of the stock is currently owned by institutional investors.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
Recommended Story: Moving Average – How it Helps Investors in Stock Selection
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.